Advanced Lung Cancer (Stage IV & SCLC): Targeted Therapies, ADCs & T-Cell Engagers

Stage IV NSCLC With Driver Mutations: Oral Precision Tablets

When an actionable genomic driver is detected, targeted tyrosine kinase inhibitors (TKIs) replace standard intravenous chemotherapy as the first-line treatment of choice:

• EGFR Mutations: Osimertinib (either monotherapy or combined with platinum pemetrexed chemotherapy) delivers high systemic and central nervous system (CNS) disease control.
• ALK Rearrangements: Alectinib or lorlatinib serve as premier first-line therapies. Remarkable 7-year follow-up data for lorlatinib documented the longest progression-free survival ever reported in advanced NSCLC, with superior protection against brain metastases.
• ROS1 & HER2 Approvals: In 2026, the FDA approved zidesamtinib for previously treated ROS1-positive disease, and sevabertinib for HER2-mutant non-squamous NSCLC (including first-line use).
• RET, MET & KRAS G12C: Specific oral inhibitors (selpercatinib, capmatinib, sotorasib, adagrasib) offer tailored alternatives, with KRAS G12C combinations rapidly moving into first-line settings.

Stage IV NSCLC Without Driver Mutations: The Power of Immunotherapy

For tumors without actionable driver alterations, therapy is directed by PD-L1 expression levels on tumor cells:

• High PD-L1 (TPS >= 50%): Monotherapy with immune checkpoint inhibitors (pembrolizumab, atezolizumab, or cemiplimab) stimulates the patient's own T cells without the toxicity of chemotherapy.
• Low or Negative PD-L1: Dual therapy combining platinum doublet chemotherapy with immune checkpoint blockade overcomes immune evasion and ensures rapid tumor reduction.

Antibody-Drug Conjugates (ADCs) & Bispecific Antibodies

ADCs represent 'biological smart bombs'—engineered monoclonal antibodies linked to potent cytotoxic payloads that release their drug only upon binding tumor-specific surface proteins:

• Datopotamab Deruxtecan (Dato-DXd): Validated and approved for pretreated EGFR-mutated NSCLC, circumventing traditional resistance mechanisms.
• Telisotuzumab Vedotin: Targets tumors overexpressing c-Met protein, delivering targeted cell death.
• Bispecific Antibodies (Ivonescimab): Novel dual-action antibodies that simultaneously neutralize PD-1 and VEGF pathways, showing remarkable anti-tumor synergy in squamous and non-squamous NSCLC.

Small Cell Lung Cancer (SCLC): Major Therapeutic Leaps

SCLC is notoriously rapid-growing but uniquely responsive to modern immunotherapy combinations:

• Limited-Stage SCLC: Standard chemoradiotherapy followed by consolidative durvalumab (based on the landmark ADRIATIC trial) significantly prolongs overall survival.
• Extensive-Stage SCLC: Frontline chemotherapy combined with atezolizumab or durvalumab, with maintenance lurbinectedin plus atezolizumab approved in 2025 (IMforte trial).
• Relapsed SCLC & Tarlatamab: Tarlatamab—a first-in-class bispecific T-cell engager (BiTE)—physically links patient cytotoxic T cells directly to DLL3 proteins on SCLC cells, demonstrating superior survival over standard chemotherapy.

Oligometastases, Brain Protection & Early Palliative Care

Two vital clinical principles reshape Stage IV lung cancer outcomes: First, patients with oligometastatic disease (isolated spread to 1-3 sites) benefit from stereotactic radiosurgery (SRS) or surgical ablation alongside systemic tablets. Second, palliative care must begin at diagnosis rather than end-of-life—proactively addressing pain, dyspnea, nutrition, and psychological resilience improves both survival duration and quality of life.

Dr. Sujata Mittal, Senior Surgical & Gynaecologic Oncologist, Famicare Speciality Center, Rohini, Delhi